Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 9/20 | 0.39 |
| ▸ | BRD1 | O95696 | 6/20 | 0.39 |
| ▸ | BRPF3 | Q9ULD4 | 6/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.39 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | USP14 | P54578 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | GPR6 | P46095 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29471259 | 1.00 | BRPF1 (0.39) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL31542345 | 0.86 | BRPF1 (0.35) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL24317223 | 0.86 | RXFP1 (0.38) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL29471157 | 0.86 | RXFP1 (0.38) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL31542279 | 0.86 | BRPF1 (0.35) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL24316561 | 0.84 | BRPF1 (0.40) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL31542282 | 0.83 | BRPF1 (0.37) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL29471262 | 0.83 | MAPT (0.37) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL26548555 | 0.83 | MAPT (0.37) | BRPF1BRD1BRPF3BRD4BRD9 | |
| SCHEMBL24317222 | 0.82 | MAPT (0.35) | BRPF1TP53EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| EP-4210683-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | Aurigene Oncology Limited (IN) | 2023-07-19 | — | — | EP | disclosed |
| CN-116368128-A | Heterocyclic compounds as CBP/EP300 bromodomain inhibitors | 奥瑞基尼肿瘤有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022053967-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | BRPF1 216/4885BRD1 15/4885BRPF3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.